Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue

Cancer Research

Volumn 60, Issue 5, 2000, Pages 1317-1325

  Tamura, Kenji ^a,d   Southwick, Eileen C ^a   Kerns, Jeffrey ^b   Rosi, Katherine ^b   Carr, Brian I ^c   Wilcox, Craig ^b   Lazo, John S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 MERCAPTOETHANOL) 3 METHYL 1,4 NAPHTHOQUINONE; PROTEIN KINASE C INHIBITOR; PROTEIN P16; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TYROSINE; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PHOSPHORYLATION; PRIORITY JOURNAL;

CDC25 PHOSPHATASE; CELL CYCLE; GROWTH INHIBITORS; HUMANS; MERCAPTOETHANOL; NAPHTHOQUINONES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VITAMIN K;

EID: 0034163387     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ngo, E. O., Sun, T-P., Chang, J-Y., Wang, C. C., Chi, K-H., and Nutter, L. M. Status of glutathione and glutathione-metabolizing enzymes in menadione-resistant human cancer cells. Biochem. Pharmacol., 42: 1961-1968, 1991.
2. 3 oxide inhibit growth of Hep3B and HepG2 cells. Bioorg. Chem., 23: 101-108, 1995.
3. Chlebowski, R. T., Dietrich, M., Akinan, S., and Block, J. B. Vitamin K3 inhibition of malignant mutine cell growth and human tumor colony formation. Cancer Treat. Rep., 85: 527-532, 1985.
4. Nutter, L. M., Cheng, A. L., Hung, H. L., Hsieh, R. K., Ngo, E. O., and Liu, T. W. Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem. Pharmacol., 41: 1283-1292, 1991.
5. Akman, S., Carr, B. I., Leong, L., Margolin, K., Odujinrin, O., and Doroshow, J. Phase 1 trial of menadiol sodium diphosphate in advance cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 7: 290, 1988.
6. Nutter, L. M., Ngo, E. O., Fisher, G. R., and Gutierrez, P. L. DNA strand scission and free radical production in menadione-treated cells. Correlation with cytotoxicity and role of NADPH quinone acceptor oxidoreductase. J. Biol. Chem., 267: 2474-2479, 1992.
7. Rossi, L., Moore, G. A., Orrenius, S., and O'Brien, P. J. Quinone toxicity in hepatocytes without oxidative stress. Arch. Biochem. Biophys., 251: 25-31, 1986.
8. Nishikawa, Y., Carr, B. I., Wang, M., Kar, S., Finn, F., Dowd, P., Zheng, Z. B., Kerns, J., and Naganathan, S. Growth inhibition of hepatoma cells induced by Vitamin K and its analogs. J. Biol. Chem., 47: 28304-28310, 1995.
9. Sadhu, K., Reed, S. I., Richardson, H., and Russell, P. Human homolog of fission yeast Cdc25 mitotic inducer is predominantly expressed in G2. Proc. Natl. Acad. Sci. USA, 87: 5139-5143, 1990.
10. Galaktionov, K., and Beach, D. Specific activation of Cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell, 67: 1181-1194, 1991.
11. Nagata, A., Igarashi, M., Jinno, S., Suto, K., and Okayama, H. An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells. New Biol., 3: 959-968, 1991.
12. Millar, J. B., Blevitt, J., Gerace, L., Sadhu, K., Featherstone, C., and Russell, P. p55CDC25 is a nuclear protein required for the initiation of mitosis in human cells. Proc. Natl. Acad. Sci. USA, 88: 10500-10504, 1991.
13. Jinno, S., Suto, J., Nagata, A., Igarashi, M., Kanaoka, Y., Nojima, H., and Okayama, H. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J., 13: 1549-1556, 1994.
14. Lammer, C., Wagerer, S., Saffrich, R., Mertens, D., Ansorge, W., and Hoffmann, I. The cdc25B phosphatase is essential for G2/M phase transition in human cells. J. Cell Sci., 111: 2445-2453, 1998.
15. Galaktionov, K., Lee, A. K., Eckstein, J., Draetta, G., Meckler, J., Loda, M., and Beach, D. CDC25 phosphatases as potential human oncogenes. Science (Washington DC), 269: 1575-1577, 1995.
16. Galaktionov, K., Chen, X., and Beach, D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature (Lond.), 382: 511-517, 1996.
17. Gasparotto, D., Maestro, R., Piccinin, S., Vukosavljevic, T., Barzan, L., Sulfaro, S., and Boiocchi, M. Overexpression of Cdc25A and Cdc25B in head and neck cancers. Cancer Res., 57: 2366-2368, 1997.
18. Hernandez, S., Hernandez, L., Bea, S., Cazorla, M., Fernandez, P. L., Nadal, A., Muntane, J., Mallofre, C., Montserrat, E., Cardesa, A., and Campo, E. Cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas. Cancer Res., 58: 1762-1767, 1998.
19. Wu, W., Fan, Y-H., Kemp, B. L., Walsh, G., and Mao, L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res., 58: 4082-4085, 1998.
20. Juan, C-C., and Wu, F-Y. H. Vitamin K3 inhibits growth of human hepatoma HepG2 cells by decreasing activities of both p34cdc2 kinase and phosphatase. Biochem. Biophys. Res. Commun., 190: 907-913, 1993.
21. Ham, S. W., Park, J., Lee, S. J., Kim, W., Kang, K., and Choi, K. H. Naphthoquinone analogs as inactivalors of cdc25 phosphatase. Bioorg. Med. Chem. Lett., 8: 2507-2510, 1998.
22. Th'ng, J. P., Wright, P. S., Hamaguchi, J., Lee, M. G., Norbury, C. J., Nurse, P., and Bradbury, E. M. The FT210 cell line is a mouse G2 phase mutant with a temperature-sensitive CDC2 gene product. Cell, 63: 313-324, 1990.
23. Rice, R. L., Rusnak, J. M., Yokokawa, F., Yokokawa, S., Messner, D. J., Boynton, A. L., Wipf, P., and Lazo, J. S. A targeted library of small molecule, tyrosine and dual specificity phosphatase inhibitors derived from a rational core design and random side chain variation. Biochemistry, 36: 15965-15974, 1997.
24. Kakeya, H., Onose, R., Liu, C-C. P., Onozawa, C., Matsumura, F., and Osada, H. Inhibition of Cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic. Cancer Res., 58: 704-710, 1998.
25. Vogt, A., Rice, R. L., Settineri, C. E., Yokokawa, F., Yokokawa, S., Wipf, P., and Lazo, J. S. Disruption of insulin-like growth factor-1 signaling and down-regulation of Cdc2 by SC-ααδ9, a novel small molecule antisignaling agent identified in a targeted array library. J. Pharmacol. Exp. Ther., 287: 806-813, 1998.
26. Yu, L., Orlandi, L., Wang, P., Orr, M. S., Senderowicz, A. M., Sausville, E. A., Silvestrini, R., Watanabe, N., Piwnica-Worms, H., and O'Connor, P. M. UCN-01 arrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee 1 Hu kinase and activation of the Cdc25C phosphatase. J. Biol. Chem., 273: 33455-33454, 1998.
27. Tamura, K., Rice, R. L., Wipf, P., and Lazo, J. S. Dual G1 and G2/M phase inhibition by SC-ααδ9, a combinatorially derived Cdc25 phosphatase inhibitor. Oncogene, 18: 6989-6996, 2000.
28. Strausfeld, U., Labbe, J. C., Fesquet, D., Cavadore, J. C., Picard, A., Sadhu, K., Russell, P., and Doree, M. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature (Lond.), 351: 242-245, 1991.
29. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
30. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
31. Hoffman, I., Draetta, G., and Karsenti, E. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J., 13: 4302-4310, 1994.
32. Fauman, E. B., Cogswell, J. P., Lovejoy, B., Rocque, W. J., Holmes, W., Montana, V. G., Piwnica-Worms, H., Rink, M. J., and Saper, M. A. Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell, 93: 617-625, 1998.
33. cdc13 protein kinase. Anticancer Res., 12: 873-880, 1992.
34. Peng, H., Zalkow, L. H., Abraham, R. T., and Powis, G. Novel CDC25A phosphatase inhibitors from pyrolysis of 3-α-azido-B-homo-6-oxa-4-cholesten-7-one on silica gel. J. Med. Chem., 41: 4677-4680, 1998.
35. Horiguchi, T., Nishi, K., Hakoda, S., Tanida, S., Nagata, A., and Okayama, H. Dnacin A1 and Dnacin B1 are antitumor antibiotics that inhibit cdc25B phosphatase activity. Biochem. Pharmacol., 48: 2139-2141, 1994.
36. Ni, R., Nishikawa, Y., and Carr, B. I. Cell growth inhibition by a novel vitamin K is associated with induction of protein tyrosine phosphorylation. J. Biol. Chem., 272: 9906-9911, 1998.
37. Terada, Y., Tatsuka, M., Jinno, S., and Okayama, H. Requirement for tyrosine phosphorylation of Cdk4 in G1 arrest induced by ultraviolet irradiation. Nature (Lond.), 376: 358-362, 1995.
38. Hermeking, H., Lengauer, C., Polyak, K., He, T. C., Zhang, L., Thiagalingam, S., Kinzler, K. W., and Vogelstein. B. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol. Cell. 1: 3-11, 1997.
39. Nishikawa, Y., Wang, Z., Kerns, J., Wilcox, C. S., and Carr. B. I. Inhibition of hepatoma cell growth in vitro by arylating and non-arylating K vitamin analogs. J. Biol. Chem., 274: 34803-34810, 1999.